Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
Tuesday, February 11, 2025Arrowhead Pharmaceuticals Inc today announced that the global licensing and collaboration agreement with Sarepta Therapeutics NASDAQ SRPT announced on November has now closed Closing of the transaction was subject to the expiration or termination o...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
Monday, February 10, 2025Eli Lilly and Company announced results from the VIVID openlabel extension study which showed the majority of patients with moderately to severely active Crohns disease receiving two years of continuous treatment with Omvoh mirikizumabmrkz achieved l...
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
Monday, February 10, 2025Global biotechnology leader CSL announced the fouryear results from the pivotal HOPEB study confirming the longterm durability and safety of a onetime infusion of HEMGENIX etranacogene dezaparvovecdrlb for adults living with hemophilia B In an oral p...
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
Friday, February 07, 2025Rakovina Therapeutics Inc a biopharmaceutical company advancing cancer therapies based on DNAdamage response technologies announces continued advancement of its AIdriven drug discovery program
Essential Pharma and Clinigen Expand Collaboration to Improve Patient Access in JAPAC
Friday, February 07, 2025Essential Pharma an international specialty pharma group focused on ensuring that patients have access to low volume clinically differentiated niche pharmaceutical products across key therapeutic areas and Clinigen the global specialty pharmaceutical...
Ultragenyx Presents New Data Showing Significant Clinical Improvement with UX111 AAV Gene Therapy in Children with Sanfilippo Syndrome Type A (MPS IIIA), Linked to Sustained Reductions in CSF-HS
Thursday, February 06, 2025Ultragenyx Pharmaceutical Inctoday announced new data demonstrating treatment with UX ABO AAV gene therapy led to a statistically significant improvement in the BayleyIIIi raw scores for the subdomains of cognition receptive communication and express...
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
Thursday, February 06, 2025EyePoint Pharmaceuticals Inc a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases today announced positive sixmonth results for the ongoing Phase VERONA clinical...
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing
Wednesday, February 05, 2025Auron Therapeutics a clinicalstage biotechnology company targeting cellstate plasticity to improve patient outcomes in oncology and inflammatory disease today announced progress for its lead KATAB program and clinical candidate AUTX and the completio...
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America
Wednesday, February 05, 2025Ardena a specialist pharmaceutical Contract Development and Manufacturing Organization CDMO and bioanalytical Contract Research Organization CRO with facilities in Belgium Spain the Netherlands and Sweden today announced that it has successfully comp...
Avirmax Biopharma Announces Completion of the First Cohort of Patient Enrollment in Clinical Trial of ABI-110, a Gene Therapy for Wet AMD Including PCV
Tuesday, February 04, 2025Avirmax Biopharma Inc a leader in the development of the next generation of AAV gene therapies today announced completion of the first cohort of the Phase IIIa clinical trial of ABI the companys gene therapy drug for the treatment
